XML 14 R10.htm IDEA: XBRL DOCUMENT
v3.19.3

EARNINGS PER SHARE | 9 Months Ended
--- | ---
Sep. 30, 2019
Earnings Per Share, Basic and Diluted [Abstract] |
EARNINGS (LOSS) PER SHARE | EARNINGS PER SHARE The computation of basic and diluted earnings per common share was as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Amounts attributable to Quest Diagnostics’ common stockholders: |  |  |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 215 |  |  | $ | 213 |  |  | $ | 585 |  |  | $ | 609 |
Income from discontinued operations, net of taxes | — |  |  | — |  |  | 20 |  |  | — |
Net income attributable to Quest Diagnostics’ common stockholders | $ | 215 |  |  | $ | 213 |  |  | $ | 605 |  |  | $ | 609 |
Income from continuing operations | $ | 215 |  |  | $ | 213 |  |  | $ | 585 |  |  | $ | 609 |
Less: Earnings allocated to participating securities | 1 |  |  | 1 |  |  | 2 |  |  | 2 |
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted | $ | 214 |  |  | $ | 212 |  |  | $ | 583 |  |  | $ | 607 |
Weighted average common shares outstanding – basic | 135 |  |  | 136 |  |  | 135 |  |  | 136 |
Effect of dilutive securities: |  |  |  |  |  |  |  |  |  |  |
Stock options and performance share units | 2 |  |  | 3 |  |  | 1 |  |  | 3 |
Weighted average common shares outstanding – diluted | 137 |  |  | 139 |  |  | 136 |  |  | 139 |
Earnings per share attributable to Quest Diagnostics’ common stockholders - basic: |  |  |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 1.59 |  |  | $ | 1.56 |  |  | $ | 4.33 |  |  | $ | 4.46 |
Income from discontinued operations | — |  |  | — |  |  | 0.15 |  |  | — |
Net income | $ | 1.59 |  |  | $ | 1.56 |  |  | $ | 4.48 |  |  | $ | 4.46 |
Earnings per share attributable to Quest Diagnostics’ common stockholders – diluted: |  |  |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 1.56 |  |  | $ | 1.53 |  |  | $ | 4.27 |  |  | $ | 4.37 |
Income from discontinued operations | — |  |  | — |  |  | 0.15 |  |  | — |
Net income | $ | 1.56 |  |  | $ | 1.53 |  |  | $ | 4.42 |  |  | $ | 4.37 |
The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2019 |  | 2018 |  | 2019 |  | 2018
Stock options | 2 |  |  | 2 |  |  | 3 |  |  | 2 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareBasicAndDilutedAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration